Identification of KIF26B as a Tumor Marker for Oral Squamous Cell Carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Kinesin family member 26B (KIF26B) is upregulated in oral squamous cell carcinoma (OSCC), promoting tumor progression. Inhibiting KIF26B may offer a therapeutic strategy for OSCC.
Area Of Science
- Oncology
- Molecular Biology
- Cell Biology
Background
- Kinesin family member 26B (KIF26B) is implicated in various cancers.
- Limited research exists on KIF26B's role in oral squamous cell carcinoma (OSCC).
Purpose Of The Study
- To investigate KIF26B expression levels in OSCC.
- To elucidate the mechanisms underlying KIF26B's function in OSCC pathogenesis and progression.
Main Methods
- RT-qPCR and Western blot to quantify KIF26B expression in OSCC tissues and cell lines.
- In vitro assays (EdU, clone formation, Transwell) to assess proliferation, migration, and invasion.
- Analysis of the GSK-3β/β-catenin pathway.
Main Results
- KIF26B expression is significantly higher in OSCC tissues than normal tissues.
- KIF26B overexpression enhances OSCC cell proliferation, migration, and invasion.
- KIF26B influences the GSK-3β/β-catenin pathway, affecting β-catenin and c-myc levels.
Conclusions
- KIF26B acts as an oncogene in OSCC development and progression.
- KIF26B represents a potential therapeutic target for OSCC treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.